Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | January 02, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Quince Therapeutics, Inc.
Report date January 02, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2036-01-02 | Direct | 18,724 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 18,724 · Balance 18,724 F1: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 00:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002975 · tm262917-2_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 22:59 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 18,724 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000083 · form4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,724 Underlying: Common Shares · 18,724 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:07 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000613 · form4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:32 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (right to buy) · Derivative | 30,282 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001163 · form4-01092025_120106.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,282 Underlying: Common Stock · 30,282 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070514 · tm2416928-1_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 00:59 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016089 · form4-06082024_120627.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075875 · tm2319786-6_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:45 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-032671 · doc4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:20 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-22-035877 · doc4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of June 9, 2022. Read SEC document |
| May 19, 2022 Filed May 23, 2022 22:50 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001104659-22-063973 · tm2216669-4_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:32 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001104659-21-081586 · tm2119762-5_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-11 F1 · derivative.exercise_date: The option will vest in full and become exercisable in three substantially equal annual installments following the date of grant, such that the option shall be fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 4,167 | $0.00 Strike: $55.71 | $0.00 |
DisclosureSEC source: 0001104659-21-031663 · tm217124-6_4seq1.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2021-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of the earlier of the first anniversary of March 1, 2021 or the day immediately prior to the start of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.